Anifrolumab
D346BC00001
Phase 3 other active
Quick answer
Anifrolumab for Cutaneous Lupus Erythematosus is a Phase 3 program (other) at AstraZeneca with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca
- Indication
- Cutaneous Lupus Erythematosus
- Phase
- Phase 3
- Modality
- other
- Status
- active